Skip to header Skip to main navigation Skip to main content Skip to footer

OpenAI Cuts Its Funding Target to 20 Billion Dollars After a Tepid Response From Big Investors

Breadcrumb

  • Home
  • OpenAI Cuts Its Funding Target to 20 Billion Dollars After a Tepid Response From Big Investors

OpenAI's latest funding round is not landing the way the last ones did. The Financial Times reported on Friday that the company has lowered its target to 20 billion dollars, with a first close expected to come in lower still, and The Wall Street Journal added that OpenAI has so far secured roughly 11 billion dollars in commitments after a tepid response from some large investors. That is less than half of the 30 billion dollars the company initially targeted, and the deal now values OpenAI at 1.25 trillion dollars rather than the 1.4 trillion it had hoped for. The round is being led by a group of investors from the United Arab Emirates, and OpenAI has told shareholders it will spend the coming weeks courting family offices and wealthy individuals — a retail-style offering to rich buyers could be what gets the total to 20 billion. TechCrunch reached out to OpenAI for comment and had no reply at publication.

Timing explains a lot of it. The reports land at the end of a brutal week for the AI trade, in which Alphabet, Amazon, Meta and Microsoft outlined more than 740 billion dollars of infrastructure spending for the year and investors answered by selling: the Nasdaq fell 2.9 percent on Friday, and Alphabet suffered its worst day on record on Thursday. OpenAI is also trying to raise ahead of an initial public offering that could come as soon as early next year, and the comparison with its chief rival is not flattering. The Journal has reported that Anthropic managed a small operating profit in the second quarter while OpenAI's operating losses deepened over the same period — and Anthropic's own planned IPO is reportedly facing a high junk credit rating, so neither lab is immune to the new mood.

Regulators are starting to circle the same question investors are asking. Reuters reported on October 30 that the Securities and Exchange Commission is examining AI companies' corporate disclosures amid worries that circular deals have helped inflate a bubble. Enforcement director David Woodcock, who took the job in May, put it plainly: the agency's principal concern is that issuers give investors the full picture on material risks, and where accurate disclosure does not happen, enforcement will be present. He also said to expect more SEC activity around private-market valuations and conflicts of interest — precisely the arena where trillion-dollar private rounds like this one get priced.

For people building with AI, the headline is not that OpenAI is running out of money — 11 billion dollars secured is still an enormous raise by any normal standard. The shift is in leverage. For three years the frontier labs set the price and the market paid it; this week the market pushed back on the biggest name in the field, at the same moment the SEC started asking whether AI disclosures say enough about the risks underneath the spending. Expect that discipline to travel downstream: harder questions in enterprise procurement about vendor finances, less tolerance for loss-leader API pricing that can vanish at renewal, and more value in architectures that can swap providers when a contract or a balance sheet changes. The labs will still get their capital. They will just have to argue for it now — and builders should plan as if the era of subsidized certainty is ending.

Rocky Mountain Madman LLC
OpenAI
AI Funding
Enterprise AI
Frontier Models
AI Regulation

Ai Industry News

OpenAI Buys Orchestra Bio to Put Agents on the Unglamorous Side of Drug Development

OpenAI announced on Tuesday, October 20, that it has acquired Orchestra Bio, a four-year-old biotech software startup whose AI agents handle the operational grind of drug development. Terms were not disclosed. Orchestra had reportedly raised around 20 million dollars as of 2025 from backers including Andreessen Horowitz, Atria, and 8VC, according to TechCrunch. Its platform helps biotech companies track the minutiae of getting a drug through development, from finances to resolving scheduling problems with clinical trials.

  • Read more about OpenAI Buys Orchestra Bio to Put Agents on the Unglamorous Side of Drug Development

OpenAI Races to Raise 30 Billion Dollars Before Anthropic Sets the Market Price

OpenAI CEO Sam Altman speaking on stage at TechCrunch Disrupt.

OpenAI is accelerating a fundraising round of about 30 billion dollars that could value the company at more than 1.4 trillion dollars, Reuters reported on Monday, citing people familiar with the matter. The push is deliberately timed ahead of Anthropic's expected stock market debut in mid-November. Existing backers SoftBank Group and Abu Dhabi-based MGX are in talks to join, and OpenAI met with long-only funds and sovereign wealth funds last week, in the same week Anthropic was holding its own investor day. OpenAI and SoftBank declined to comment to Reuters.

  • Read more about OpenAI Races to Raise 30 Billion Dollars Before Anthropic Sets the Market Price

Another 45 Billion Dollars: Anthropic and Nscale Are Reportedly Talking About Doing It Again

Anthropic and AI infrastructure provider Nscale are reportedly on the verge of announcing a second compute deal worth 45 billion dollars, according to Bloomberg reporting relayed by TechCrunch on October 19. The talks would come a little over a month after the two companies announced a first 45 billion dollar compute deal. Bloomberg's sources, cited by TechCrunch, cautioned that the talks are still underway and the details could change, and TechCrunch said it had reached out to both companies for comment.

  • Read more about Another 45 Billion Dollars: Anthropic and Nscale Are Reportedly Talking About Doing It Again

Pagination

  • First page « First
  • Previous page ‹ Previous
  • …
  • Page 8
  • Page 9
  • Page 10
  • Page 11
  • Current page 12
  • Page 13
  • Page 14
  • Page 15
  • Page 16
  • …
  • Next page Next ›
  • Last page Last »

Copyright © 2026 Rocky Mountain Madman LLC - All rights reserved

Developed and Designed by Rocky Mountain Madman LLC